Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 12/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6467012 | 0.81 | ADRA2A (0.48) | TACR1ADRA2AMCHR1RXFP1USP2 | |
| SCHEMBL6460870 | 0.76 | KDM4E (0.52) | ADRA2AMCHR1RXFP1USP2 | |
| SCHEMBL6462481 | 0.73 | KDM4E (0.50) | ADRA2AMCHR1RXFP1 | |
| SCHEMBL6464250 | 0.73 | LMNA (0.50) | ADRA2AMCHR1RXFP1 | |
| SCHEMBL6462855 | 0.72 | MCHR1 (0.41) | MCHR1 | |
| SCHEMBL6457061 | 0.71 | KDM4E (0.48) | ADRA2AMCHR1 | |
| SCHEMBL6459355 | 0.71 | MCHR1 (0.46) | MCHR1 | |
| SCHEMBL6879281 | 0.70 | MCHR1 (0.58) | ADRA2AMCHR1RXFP1 | |
| SCHEMBL6879276 | 0.70 | MCHR1 (0.58) | ADRA2AMCHR1RXFP1 | |
| SCHEMBL5524846 | 0.70 | MCHR1 (0.51) | ADRA2AMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | TACR1 115/4885CCR2 661/4885ADRA2A 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.